Acadia Pharmaceuticals Stock In The News
| ACAD Stock | USD 17.57 0.05 0.29% |
Our overall analysis of ACADIA Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards ACADIA Pharmaceuticals. The specific impact of ACADIA Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of ACADIA Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using ACADIA Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out ACADIA Pharmaceuticals Backtesting and ACADIA Pharmaceuticals Hype Analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
ACADIA |
ACADIA Pharmaceuticals Today Top News and Investor Outlook
ACADIA Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide ACADIA and other traded companies coverage with news coverage. We help investors stay connected with ACADIA headlines for the 19th of January to make an informed investment decision based on correlating the impacts of news items on ACADIA Stock performance. Please note that trading solely based on the ACADIA Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
ACADIA Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the ACADIA earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about ACADIA Pharmaceuticals that are available to investors today. That information is available publicly through ACADIA media outlets and privately through word of mouth or via ACADIA internal channels. However, regardless of the origin, that massive amount of ACADIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ACADIA Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ACADIA Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ACADIA Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ACADIA Pharmaceuticals alpha.
ACADIA Largest EPS Surprises
Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-06 | 2024-06-30 | 0.18 | 0.2 | 0.02 | 11 | ||
2022-11-02 | 2022-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2013-08-06 | 2013-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2013-03-12 | 2012-12-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2012-08-08 | 2012-06-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2011-08-10 | 2011-06-30 | -0.14 | -0.12 | 0.02 | 14 |
ACADIA Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to ACADIA Pharmaceuticals Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
17th of January 2025
ACADIA Pharmaceuticals Inc Announces Inducement Awards for New Employees at gurufocus.com
15th of January 2025
Why CAR Group, Myer, Neuren, and Yancoal shares are falling today at fool.com.au
14th of January 2025
ACADIA Pharmaceuticals Submits MAA for Trofinetide to EMA at gurufocus.com
2nd of January 2025
Why ACADIA Pharmaceuticals Inc. Is Skyrocketing at insidermonkey.com
31st of December 2024
Heres Why Acadia Pharmaceuticals is a Strong Momentum Stock at finance.yahoo.com
19th of December 2024
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on ... at finance.yahoo.com
16th of December 2024
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 at finance.yahoo.com
12th of December 2024
ACADIA HEALTHCARE SHAREHOLDER ALERT CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF... at gurufocus.com
3rd of December 2024
Why Acadia Pharmaceuticals is a Top Momentum Stock for the Long-Term at zacks.com
19th of November 2024
ACADIA HEALTHCARE ALERT Bragar Eagel Squire, P.C. ... at gurufocus.com
7th of November 2024
ACADIA Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Sales Growth and ... at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ACADIA Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ACADIA Pharmaceuticals' short interest history, or implied volatility extrapolated from ACADIA Pharmaceuticals options trading.
Check out ACADIA Pharmaceuticals Backtesting and ACADIA Pharmaceuticals Hype Analysis. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share | Quarterly Revenue Growth 0.183 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.